Back to Results

Spyre Therapeutics Inc (SYRE)

Featured in High-Beta Momentum

-


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-SYRE
$49.51
-45.2% Downside
Overvalued
$122.33
35.4% Upside
Undervalued
Good
0.0%
November 5, 2026
8.8x
8.442 B
7.443 B
0.0%
93.6%
69.4
139.1%
Valuation • Fair Value

Spyre Therapeutics Inc (NASDAQ-SYRE) Fair Value by Valuation Model

Review the available estimates for Spyre Therapeutics Inc (NASDAQ-SYRE), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$49.51

Estimated downside of 45.2% versus the current market price.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

DCF Fair Value

$37.10

Discounted cash flow valuation reference.

Comps Fair Value

$52.62

Comparable-company valuation reference.

Analyst Price Target

$122.33

Analysts imply upside of 35.4%.

How to read these valuation models

Use the 5 available valuation references for Spyre Therapeutics Inc (NASDAQ-SYRE) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Spyre Therapeutics Inc (NASDAQ-SYRE)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-201.3 M

Current operating profitability reference.

EBITDA Forecast

-260.2 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Spyre Therapeutics Inc (NASDAQ-SYRE) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Spyre Therapeutics Inc (NASDAQ-SYRE)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Good

Positive financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Altman Z-Score

69.4

Relatively strong balance-sheet zone.

FCF / Net Income

139.1%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Spyre Therapeutics Inc (NASDAQ-SYRE). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Spyre Therapeutics Inc (NASDAQ-SYRE)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 5, 2026

Days to Earnings

12

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Spyre Therapeutics Inc (NASDAQ-SYRE), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Spyre Therapeutics Inc (NASDAQ-SYRE) Stock Forecast & Technical Outlook

Review Spyre Therapeutics Inc (NASDAQ-SYRE) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Spyre Therapeutics Inc (NASDAQ-SYRE) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Sell

The 1-hour technical read for Spyre Therapeutics Inc (NASDAQ-SYRE) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Buy

The daily technical read for Spyre Therapeutics Inc (NASDAQ-SYRE) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Neutral

The weekly technical read for Spyre Therapeutics Inc (NASDAQ-SYRE) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Spyre Therapeutics Inc (NASDAQ-SYRE) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Spyre Therapeutics Inc (NASDAQ-SYRE)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Spyre Therapeutics Inc (NASDAQ-SYRE) has a Strong Buy consensus, with 16 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 16
Hold 1
Sell 0
FAQ • Fast Investor Answers

Spyre Therapeutics Inc (NASDAQ-SYRE) Stock FAQ

Data-supported answers about Spyre Therapeutics Inc (NASDAQ-SYRE), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$49.51
Estimated downside 45.2%
Valuation Rating
Overvalued
Estimated downside of 45.2%
Analyst Target
$122.33
Implied upside 35.4%
Financial Health
Good
Current financial-health read

The current fair value estimate for Spyre Therapeutics Inc (NASDAQ-SYRE) is $49.51. This implies an estimated downside of 45.2% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 45.2% versus the current market price.

The available analyst price target for Spyre Therapeutics Inc (NASDAQ-SYRE) is $122.33. The analyst target implies estimated upside of 35.4%.

The current financial health read for Spyre Therapeutics Inc (NASDAQ-SYRE) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Spyre Therapeutics Inc (NASDAQ-SYRE) is November 5, 2026.

The latest available data indicates no current dividend yield for Spyre Therapeutics Inc (NASDAQ-SYRE).

The current market capitalization listed for Spyre Therapeutics Inc is 8.442 B.

The current enterprise value listed for Spyre Therapeutics Inc is 7.443 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Spyre Therapeutics Inc is NASDAQ-SYRE, and the stock is listed on NASDAQ.

Spyre Therapeutics Inc (NASDAQ-SYRE) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Spyre Therapeutics Inc is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Spyre Therapeutics Inc is 93.6%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 504.8 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 237.5 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 193.5 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 132.8 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.385 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 79.887 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 58.227 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 54.76 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 42.937 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Overvalued Market Cap 40.079 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 37.04 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 29.977 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 26.358 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 25.198 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 23.663 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 23.454 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 22.135 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 20.395 B
EXEL NASDAQ Exelixis Inc Fair Value Overvalued Market Cap 15.989 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.983 B